Comparison of real costs in the French healthcare system in newly diagnosed pemphigus patients: first-line treatment with rituximab versus standard corticosteroid regimen. Data of a national multicentre trial.
CONCLUSIONS: First-line treatment of pemphigus with rituximab results in a slightly greater cost compared with a standard CS regimen.
PMID: 31657454 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Hébert V, Vermeulin T, Tanguy L, Tedbirt B, Mignard C, Bénichou J, Joly P Tags: Br J Dermatol Source Type: research
More News: Corticosteroid Therapy | Dermatology | France Health | Pemphigus | Prednisone | Rituxan | Skin | UK Health